Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Marina Tadolini; Luigi Ruffo Codecasa; José-María García-García; François-Xavier Blanc; Sergey Borisov; Jan-Willem Alffenaar; Claire Andréjak; Pierre Bachez; Pierre-Alexandre Bart; Evgeny Belilovski; José Cardoso-Landivar; Rosella Centis; Lia D'Ambrosio; María- Luiza De Souza-Galvão; Angel Dominguez-Castellano; Samir Dourmane; Mathilde Fréchet Jachym; Antoine Froissart; Vania Giacomet; Delia Goletti; Soazic Grard; Gina Gualano; Armine Izadifar; Damien Le Du; Margarita Marín Royo; Jesica Mazza-Stalder; Ilaria Motta; Catherine Wei Min Ong; Fabrizio Palmieri; Frédéric Rivière; Teresa Rodrigo; Denise Rossato Silva; Adrián Sánchez-Montalvá; Matteo Saporiti; Paolo Scarpellini; Frédéric Schlemmer; Antonio Spanevello; Elena Sumarokova; Eva Tabernero; Paul Anantharajah Tambyah; Simon Tiberi; Alessandro Torre; Dina Visca; Miguel Zabaleta Murguiondo; Giovanni Sotgiu; Giovanni Battista Migliori

doi:10.1183/13993003.01398-2020

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Eur Respir J. 2020 Jul 9;56(1):2001398. doi: 10.1183/13993003.01398-2020. Print 2020 Jul.

Authors

Marina Tadolini^{1

2}, Luigi Ruffo Codecasa^{3

2}, José-María García-García⁴, François-Xavier Blanc⁵, Sergey Borisov⁶, Jan-Willem Alffenaar^{7

8

9}, Claire Andréjak¹⁰, Pierre Bachez¹¹, Pierre-Alexandre Bart¹², Evgeny Belilovski⁶, José Cardoso-Landivar¹³, Rosella Centis¹⁴, Lia D'Ambrosio¹⁵, María- Luiza De Souza-Galvão¹³, Angel Dominguez-Castellano¹⁶, Samir Dourmane¹⁷, Mathilde Fréchet Jachym¹⁸, Antoine Froissart¹⁹, Vania Giacomet²⁰, Delia Goletti²¹, Soazic Grard²², Gina Gualano²³, Armine Izadifar²⁴, Damien Le Du¹⁸, Margarita Marín Royo²⁵, Jesica Mazza-Stalder²⁶, Ilaria Motta²⁷, Catherine Wei Min Ong^{28

29}, Fabrizio Palmieri²³, Frédéric Rivière³⁰, Teresa Rodrigo⁴, Denise Rossato Silva³¹, Adrián Sánchez-Montalvá^{32

33

34}, Matteo Saporiti³, Paolo Scarpellini³⁵, Frédéric Schlemmer³⁶, Antonio Spanevello^{37

38}, Elena Sumarokova⁶, Eva Tabernero³⁹, Paul Anantharajah Tambyah^{28

29}, Simon Tiberi^{40

41}, Alessandro Torre⁴², Dina Visca^{37

38}, Miguel Zabaleta Murguiondo⁴³, Giovanni Sotgiu⁴⁴, Giovanni Battista Migliori⁴⁵

Affiliations

¹ Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
² Co-first authors.
³ TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy.
⁴ Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain.
⁵ Centre Hospitalier Universitaire, Nantes, France.
⁶ Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation.
⁷ The University of Sydney, Sydney Pharmacy School, Sydney, Australia.
⁸ Westmead Hospital, Sydney, Australia.
⁹ Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.
¹⁰ Service de Pneumologie CHU AMIENS PICARDIE, France AND UR Université de Picardie Jules Verne, Amiens, France.
¹¹ Service de Pneumologie, Clinique Saint Luc, Bouge, Belgium.
¹² Dept of Internal Medicine, Lausanne University, Lausanne, Switzerland.
¹³ Servicio Neumología, Vall D´Hebron University Hospital, Barcelona, Spain.
¹⁴ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
¹⁵ Public Health Consulting Group, Lugano, Switzerland.
¹⁶ Servicio de Enfermedades Infecciosas y Microbiología, Hospital Virgen Macarena, Sevilla, Spain.
¹⁷ Service de Pneumologie, Groupe hospitalier sud île de France (GHSIF), Melun, France.
¹⁸ Centre Hospitalier de Bligny, Briis Sous Forges, France.
¹⁹ Service de Médecine interne, CHI de Créteil, Créteil, France.
²⁰ Pediatric Infectious Diseases Unit, Dept of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, Italy.
²¹ Translational Research Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.
²² Centre de Lutte Antituberculeuse (CLAT 38), Grenoble, France.
²³ Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.
²⁴ Hôpital Européen de Paris La Roseraie, Aubervilliers, France.
²⁵ Servicio Neumología, Hospital General Universitario de Castellón, Castelló, Spain.
²⁶ Pulmonary Division, Lausanne University Hospital CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
²⁷ Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italia.
²⁸ Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
²⁹ Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore.
³⁰ Hôpital d'Instruction des Armées (HIA) Percy, Clamart, France.
³¹ Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, Brazil.
³² Infectious Diseases Dept, International Health and Tuberculosis Unit, Vall d'Hebron University Hospital, Barcelona, Spain.
³³ Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
³⁴ Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain.
³⁵ Unit of Infectious Diseases, Università Vita e Salute, San Raffaele Hospital, Milan, Italy.
³⁶ Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.
³⁷ Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy.
³⁸ Dept of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Italy.
³⁹ Servicio Neumología, Hospital de Cruces, Bilbao, Spain.
⁴⁰ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁴¹ Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
⁴² Dept of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy.
⁴³ Servicio Neumología Hospital Universitario Marqués de Valdecilla, Santander, Spain.
⁴⁴ Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
⁴⁵ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy giovannibattista.migliori@icsmaugeri.it.

Abstract

Diagnostic, treatment and outcome details of 49 COVID-19 patients with concurrent or previous tuberculosis from 8 countries show varied clinical profiles https://bit.ly/369ZGGu

Publication types

Letter

MeSH terms

Adult
Aged
Antitubercular Agents / therapeutic use
Antiviral Agents / therapeutic use
Azithromycin / therapeutic use
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
COVID-19 Testing
Clinical Laboratory Techniques
Cohort Studies
Coinfection
Coronavirus Infections / complications*
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy
Drug Combinations
Emigrants and Immigrants
Female
Humans
Hydroxychloroquine / therapeutic use
Lopinavir / therapeutic use
Lung / diagnostic imaging
Male
Middle Aged
Mortality
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / drug therapy
Ritonavir / therapeutic use
SARS-CoV-2
Tomography, X-Ray Computed
Tuberculosis / complications
Tuberculosis / diagnosis
Tuberculosis / drug therapy
Tuberculosis, Pulmonary / complications*
Tuberculosis, Pulmonary / diagnosis
Tuberculosis, Pulmonary / drug therapy

Substances

Antitubercular Agents
Antiviral Agents
Drug Combinations
lopinavir-ritonavir drug combination
Lopinavir
Hydroxychloroquine
Azithromycin
Ritonavir